gefitinib has been researched along with atrasentan in 1 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (atrasentan) | Trials (atrasentan) | Recent Studies (post-2010) (atrasentan) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 358 | 41 | 108 |
| Protein | Taxonomy | gefitinib (IC50) | atrasentan (IC50) |
|---|---|---|---|
| Endothelin receptor type B | Homo sapiens (human) | 0.2221 | |
| Endothelin-1 receptor | Homo sapiens (human) | 0.0001 | |
| Endothelin-1 receptor | Rattus norvegicus (Norway rat) | 0.0002 | |
| Endothelin receptor type B | Sus scrofa (pig) | 0.315 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nakayama, M; Nishimura, K; Nonomura, N; Okuyama, A; Takayama, H | 1 |
1 other study(ies) available for gefitinib and atrasentan
| Article | Year |
|---|---|
[Molecular-targeted therapy for hormone-refractory prostate cancer].
Topics: Angiotensin Receptor Antagonists; Antineoplastic Agents; Atrasentan; Benzamides; Boronic Acids; Bortezomib; Calcitriol; Celecoxib; Cyclooxygenase 2 Inhibitors; Endothelin A Receptor Antagonists; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Male; Piperazines; Prostatic Neoplasms; Pyrazines; Pyrazoles; Pyrimidines; Pyrrolidines; Quinazolines; Sulfonamides; Thalidomide; Vitamin D | 2006 |